Prescribing information



Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

In this webinar, dermatologist Professor Miriam Wittmann and rheumatologist Dr Helena Marzo discuss the need for joint plaque psoriasis (PsO) and psoriatic arthritis (PsA) clinics and offer perspectives on how joint dermatology-rheumatology clinics can be established within a Trust, and what advantages in managing patients they can offer. They then further discuss their experiences when setting up a joint clinic.

Click here for Cosentyx® (secukinumab) prescribing information


Want to be notified of upcoming webinars?

Click the button below


CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NIHR, National Institute for Health Research; NSAID, non-steroidal anti-inflammatory drug; PsA, psoriatic arthritis.

Rate this content: 
No votes yet
UK | December 2021 | 162970

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]